Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spironolactone + losartan
- Development stage
- Unknown
- Lead developer
- Tehran University of Medical Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
spironolactone + losartan is a combination therapy being evaluated by the Tehran University of Medical Sciences for the treatment of diabetic nephropathy in patients with type 2 diabetes. Spironolactone is a small molecule mineralocorticoid receptor antagonist (MRA) that blocks the effects of aldosterone, while losartan is a small molecule angiotensin II receptor blocker (ARB) that targets the type-1 angiotensin II (AT1) receptor. The combination aims to provide a more complete blockade of the renin-angiotensin-aldosterone system (RAAS), specifically addressing the phenomenon of 'aldosterone escape' which can occur during monotherapy with ACE inhibitors or ARBs. By reducing aldosterone-mediated damage and angiotensin II-induced vasoconstriction and inflammation, the therapy is intended to decrease urinary albumin excretion and slow the progression of renal impairment.
- Other names
- spironolactone + losartan-Tehran University of Medical Sciences-diabetic nephropathy
02
Targets
MR (Mineralocorticoid receptor)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on spironolactone + losartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spironolactone + losartan.